Allergic Contact Dermatitis Linked to Emotional and Functional Decline

This article was originally published by Dermatology Times^®. This version has been lightly edited.

Allergic contact dermatitis (ACD) is a common inflammatory dermatosis affecting an estimated 15% to 20% of the general population and accounting for up to 7% of dermatology consultations.¹ Although often perceived as a localized or self-limited condition, ACD carries a meaningful psychosocial and functional burden, particularly in chronic or occupational cases.

A recently published cross-sectional study from a tertiary university hospital in Spain provides new insight into the multidimensional impact of ACD on quality of life (QOL), comparing affected patients with healthy controls and examining clinical and sociodemographic determinants of impairment.²

Conducted between January 2021 and December 2023, the study included 450 adults: 225 patients with exclusively diagnosed ACD confirmed by standardized patch testing according to the European Society of Contact Dermatitis criteria, and 225 healthy controls recruited from patient companions. The final sample exceeded the a priori power calculation, ensuring adequate statistical precision for between-group and multivariate analyses.

Participants completed three validated QOL instruments adapted to Spanish populations: the Dermatology Life Quality Index (DLQI), the EuroQol 5-Dimensions (EQ-5D-5L), and the Skindex-29. Together, these tools capture dermatology-specific burden, global health-related QOL, and emotional and functional domains. Disease severity was assessed by clinicians using the modified Investigator’s Global Assessment (mIGA) scale.

The ACD cohort had a mean disease duration of approximately 68 months, reflecting a largely chronic population. Mean mIGA scores indicated mild to moderate disease overall. Notably, more than 40% of patients reported at least one ACD-related emergency department visit in the prior year.

Marked QOL Impairment Across Instruments

Across all 3 instruments, patients with ACD demonstrated significantly worse QOL compared with controls (P < .001 for all primary comparisons).

On the DLQI, mean scores in the ACD group (8.72) were substantially higher than in controls (1.39). Over half of patients (57.8%) experienced moderate to severe impairment. Item-level analysis revealed the greatest differences in symptoms (itching, soreness, pain, stinging) and emotional domains (embarrassment, self-consciousness), followed by impact on daily activities such as shopping and housework. These findings reinforce that ACD extends beyond cutaneous discomfort to affect self-perception and routine functioning.

Similarly, EQ-5D index scores were significantly lower in the ACD group (0.867 vs 0.962 in controls), indicating reduced overall health-related QOL. Differences were evident across multiple dimensions, including pain/discomfort and anxiety/depression, and were reflected in lower self-rated health on the EQ visual analogue scale.

The Skindex-29 provided further granularity. ACD patients had markedly higher scores in Symptoms (57.33 vs 13.43), Emotions (35.55 vs 4.60), and Functioning (32.44 vs 4.17), with all differences highly significant. Pruritus, burning, water sensitivity, and feelings of humiliation or frustration were among the highest scoring items. The Functioning domain emerged as a key contributor to global impairment, underscoring the extent to which ACD disrupts occupational and social activities.

Determinants of Impairment

Multivariate analyses identified several factors associated with worse QOL.

Disease severity (mIGA) was a consistent predictor of impairment, particularly for DLQI and Skindex-29 Emotional and Functioning domains. Although ANOVA did not detect significant DLQI differences across severity categories, regression models demonstrated a significant association when adjusting for confounders. This finding supports the clinical relevance of severity assessment but also suggests that severity alone does not fully explain patient burden.

Age was positively associated with DLQI scores and negatively associated with EQ-5D index values, indicating greater impairment in older patients. Older age was also linked to worse functional outcomes on Skindex-29. Sex differences were more limited; women reported higher symptom burden on the Skindex Symptoms subscale, but no consistent differences were seen in overall QOL scores.

Lower educational attainment was associated with worse Skindex Emotional and Functioning scores, suggesting potential disparities in coping resources or health literacy. Marital status did not significantly influence outcomes.

Interestingly, disease duration correlated modestly with symptom burden but not with global QOL scores. Emergency department utilization, despite being common, was not significantly associated with QOL measures, raising questions about the adequacy of acute care management and the potential role of delayed specialist intervention.

Clinical Implications

This study is notable for its simultaneous use of three complementary, validated instruments and the inclusion of a healthy control group—methodological elements often lacking in prior ACD research. The findings confirm that ACD exerts a substantial, multidimensional burden comparable to other chronic inflammatory dermatoses.

From a clinical standpoint, the data support routine integration of QOL assessment into ACD management. Sensory symptoms such as pruritus and burning, along with emotional sequelae, are key drivers of impairment and may require targeted therapeutic strategies beyond topical anti-inflammatory therapy, including optimized itch control, patient education, and when appropriate, psychological support.

The absence of a validated, disease-specific Spanish-language QOL instrument for ACD remains a limitation. Although tools such as the ACD-Index and other contact dermatitis–specific measures have been developed internationally, cultural adaptation and validation are needed to improve precision in Spanish-speaking populations.

The cross-sectional design precludes causal inference, and recruitment from a single tertiary center may limit generalizability. Controls were selected through convenience sampling, although this approach enhanced sociodemographic comparability.

Nonetheless, the study provides robust evidence that ACD significantly impairs quality of life across physical, emotional, and functional domains. For dermatologists, these findings reinforce the importance of timely diagnosis, comprehensive patch testing, and a patient-centered approach that incorporates validated QOL measures into routine care.

References

1. Tramontana M, Hansel K, Bianchi L, Sensini C, Malatesta N, Stingeni L. Advancing the understanding of allergic contact dermatitis: from pathophysiology to novel therapeutic approaches. Front Med (Lausanne). 2023;10:1184289. Published 2023 May 22. doi:10.3389/fmed.2023.1184289
2. Navarro-Triviño FJ, Prados-Carmona Á, Ruiz-Villaverde R, Peralta-Ramírez MI. Impact of allergic contact dermatitis on health-related quality of life: a cross-sectional case-control study in a Spanish population. Contact Dermatitis. Published online February 22, 2026. doi:10.1111/cod.70116